Dagens aktienyheder 15/07/2026: Ascelia Pharma
Ascelia Pharma, Efter at aktien er faldet markant siden offentliggørelsen af den fulde Complete Response Letter (CRL) fra FDA. På det nuværende niveau er markedet begyndt at prisfastsætte de mest negative scenarier, nemlig et helt nyt klinisk studie eller ingen farbar vej gennem FDA, selvom de mindre alvorlige scenarier fortsat er forenelige med både ordlyden i det fulde CRL-brev og selskabets egne kommentarer. I en ny analyse kommentar gennemgår vi, hvad den nuværende kurs implicerer, de scenarier vi ser frem mod det kommende Type A-møde med FDA, og vores læsning af det kliniske spørgsmål, der er kernen i sagen. Læs hele vurderingen med de fire scenarier og argumenterne for og imod hvert af dem her: https://www.inderes.dk/analyst-comments/ascelia-pharma-market-is-pricing-the-downside-but-the-crl-letter-and-management-commentary-still-support-better-scenarios
Disclaimer: HC Andersen Capital modtager betaling fra de nævnte selskaber for en Digital IR abonnementsaftale.. /William Jørck d. 15/07-2026 kl. 09:19.
Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.
Read more on company page
